Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

acute myeloid leukemia, blasts more than 10 percent of bone marrow nucleated cells, high risk myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory myelodysplastic syndrome, interventional, phase1, phase2